C6081001: A Phase 1 Study of PF-07985045 in Participants with Advanced Solid Tumors
- Conditions
- KRAS mutated advanced solid tumors
- Registration Number
- 2024-517988-23-00
- Lead Sponsor
- Pfizer Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised
- Sex
- Not specified
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method